{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T13:57:58Z","timestamp":1792936678339,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,6,8]],"date-time":"2017-06-08T00:00:00Z","timestamp":1496880000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,6,8]],"date-time":"2017-06-08T00:00:00Z","timestamp":1496880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Not applicable","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s40257-017-0296-7","type":"journal-article","created":{"date-parts":[[2017,6,8]],"date-time":"2017-06-08T10:33:15Z","timestamp":1496917995000},"page":"771-787","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Clinical Signs, Pathophysiology and Management of Cutaneous Side Effects of Anti-Tumor Necrosis Factor Agents"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0708-7279","authenticated-orcid":false,"given":"Siegfried","family":"Segaert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Hermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,8]]},"reference":[{"key":"296_CR1","doi-asserted-by":"crossref","unstructured":"Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117:244\u201379.","DOI":"10.1016\/j.pharmthera.2007.10.001"},{"key":"296_CR2","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1093\/annonc\/mdi279","volume":"16","author":"S Segaert","year":"2005","unstructured":"Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 2005;16:1425\u201333.","journal-title":"Ann Oncol"},{"key":"296_CR3","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.idc.2011.08.002","volume":"25","author":"RS Wallis","year":"2011","unstructured":"Wallis RS. Biologics and infections: lessons from tumor necrosis factor blocking agents. Infect Dis Clin North Am. 2011;25:895\u2013910.","journal-title":"Infect Dis Clin North Am"},{"key":"296_CR4","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1136\/gut.2008.163642","volume":"58","author":"HH Fidder","year":"2009","unstructured":"Fidder HH, Schnitzler F, Ferrante M, Noman M, Katsanos K, Segaert S, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single center cohort study. Gut. 2009;58:501\u20138.","journal-title":"Gut"},{"key":"296_CR5","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/nrgastro.2012.125","volume":"9","author":"I Cleynen","year":"2012","unstructured":"Cleynen I, Vermeire S. Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nat Rev Gastroenterol Hepatol. 2012;9:496\u2013503.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"296_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7326\/M15-0729","volume":"164","author":"I Cleynen","year":"2016","unstructured":"Cleynen I, Van Moerkercke W, Billiet T, Vandecandelaere P, Vande Casteele N, Breynaert C, et al. Characteristics of skin lesions associated with anti-tumor necrosis factor therapy in patients with inflammatory bowel disease. Ann Intern Med. 2016;164:10\u201322.","journal-title":"Ann Intern Med"},{"key":"296_CR7","doi-asserted-by":"publisher","first-page":"R666","DOI":"10.1186\/ar1724","volume":"7","author":"M Flendrie","year":"2005","unstructured":"Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2005;7:R666\u201376.","journal-title":"Arthritis Res Ther."},{"key":"296_CR8","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/j.1365-2133.2007.07682.x","volume":"156","author":"HH Lee","year":"2007","unstructured":"Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, R\u00f6wert J, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol. 2007;156:486\u201391.","journal-title":"Br J Dermatol"},{"key":"296_CR9","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1136\/gutjnl-2012-302853","volume":"63","author":"C Tillack","year":"2014","unstructured":"Tillack C, Ehmann LM, Friedrich M, Laubender RP, Papay P, Vogelsang H, et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-\u03b3-expressing Th1 cells and IL-17A\/IL-22-expressing Th17 cells and respond to anti-IL-12\/IL-23 antibody treatment. Gut. 2014;63:567\u201377.","journal-title":"Gut"},{"key":"296_CR10","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/ajg.2015.205","volume":"110","author":"E Fr\u00e9ling","year":"2015","unstructured":"Fr\u00e9ling E, Baumann C, Cuny JF, Bigard MA, Schmutz JL, Barbaud A, et al. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience. Am J Gastroenterol. 2015;110:1186\u201396.","journal-title":"Am J Gastroenterol"},{"key":"296_CR11","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3109\/00365521.2015.1125524","volume":"51","author":"AE Hellstr\u00f6m","year":"2016","unstructured":"Hellstr\u00f6m AE, F\u00e4rkkil\u00e4 M, Kolho KL. Infliximab-induced skin manifestations in patients with inflammatory bowel disease. Scand J Gastroenterol. 2016;51:563\u201371.","journal-title":"Scand J Gastroenterol"},{"key":"296_CR12","first-page":"35","volume":"29","author":"VWM Huang","year":"2015","unstructured":"Huang VWM, Dhami N, Fedorak D, Prosser C, Shalapay C, Kroeker KI, et al. A study investigating the association of dermatological and infusion reactions to infliximab and infliximab trough levels. Can J Gastroenterol. 2015;29:35\u201340.","journal-title":"Can J Gastroenterol."},{"key":"296_CR13","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1097\/MIB.0000000000000088","volume":"20","author":"T M\u00e4lk\u00f6nen","year":"2014","unstructured":"M\u00e4lk\u00f6nen T, Wikstr\u00f6m A, Heiskanen K, Merras-Salmio L, Mustonen H, Sipponen T, et al. Skin reactions during anti-TNF\u03b1 therapy for pediatric inflammatory bowel disease: a 2-year prospective study. Inflamm Bowel Dis. 2014;20:1309\u201315.","journal-title":"Inflamm Bowel Dis"},{"key":"296_CR14","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1002\/ibd.21643","volume":"17","author":"DC Baumgart","year":"2011","unstructured":"Baumgart DC, Grittner U, Steingr\u00e4ber A, Azzaro M, Philipp S. Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patients. Inflamm Bowel Dis. 2011;17:2512\u201320.","journal-title":"Inflamm Bowel Dis"},{"key":"296_CR15","doi-asserted-by":"publisher","first-page":"7019","DOI":"10.3748\/wjg.v20.i22.7019","volume":"20","author":"M W\u0142odarczyk","year":"2014","unstructured":"W\u0142odarczyk M, Sobolewska A, W\u00f3jcik B, Loga K, Fichna J, Wi\u015bniewska-Jarosi\u0144ska M. Correlations between skin lesions induced by anti-tumor necrosis factor-\u03b1 and selected cytokines in Crohn\u2019s disease patients. World J Gastroenterol. 2014;20:7019\u201326.","journal-title":"World J Gastroenterol"},{"key":"296_CR16","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1002\/art.23835","volume":"59","author":"AN Collamer","year":"2008","unstructured":"Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum. 2008;59:996\u20131001.","journal-title":"Arthritis Rheum"},{"key":"296_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00128071-200809010-00001","volume":"9","author":"U Wollina","year":"2008","unstructured":"Wollina U, Hansel G, Koch A, Sch\u00f6nlebe J, K\u00f6stler E, Haroske G. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol. 2008;9:1\u201314.","journal-title":"Am J Clin Dermatol"},{"key":"296_CR18","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.crohns.2013.10.013","volume":"8","author":"A Afzali","year":"2014","unstructured":"Afzali A, Wheat CL, Hu JK, Olerud JE, Lee SD. The association of psoriasiform rash with anti-tumor necrosis factor[anti-TNF] therapy in inflammatory bowel disease: a single academic center case series. J Crohns Colitis. 2014;8:480\u20138.","journal-title":"J Crohns Colitis."},{"key":"296_CR19","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/apt.13352","volume":"42","author":"D Pugliese","year":"2015","unstructured":"Pugliese D, Guidi L, Ferraro PM, Marzo M, Felice C, Celleno L, et al. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study. Aliment Pharmacol Ther. 2015;42:880\u20138.","journal-title":"Aliment Pharmacol Ther"},{"key":"296_CR20","doi-asserted-by":"publisher","first-page":"3424","DOI":"10.1007\/s10620-015-3763-0","volume":"60","author":"LA George","year":"2015","unstructured":"George LA, Gadani A, Cross RK, Jambaulikar G, Ghazi LJ. Psoriasiform skin lesions are caused by anti-TNF agents used for the treatment of inflammatory bowel disease. Dig Dis Sci. 2015;60:3424\u201330.","journal-title":"Dig Dis Sci"},{"key":"296_CR21","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1097\/MIB.0000000000000757","volume":"22","author":"I Guerra","year":"2016","unstructured":"Guerra I, P\u00e9rez-Jeldres T, Iborra M, Algaba A, Monfort D, Calvet X, et al. Incidence, clinical characteristics, and management of psoriasis induced by anti-TNF therapy in patients with inflammatory bowel disease: a nationwide cohort study. Inflamm Bowel Dis. 2016;22:894\u2013901.","journal-title":"Inflamm Bowel Dis"},{"key":"296_CR22","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1080\/00365521.2016.1218541","volume":"51","author":"M Protic","year":"2016","unstructured":"Protic M, Schoepfer A, Yawalkar N, Vavricka S, Seibold F. Development of psoriasis in IBD patients under TNF-antagonist therapy is associated neither with anti-TNF-antagonist antibodies nor trough levels. Scand J Gastroenterol. 2016;51:1482\u20138.","journal-title":"Scand J Gastroenterol"},{"key":"296_CR23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1136\/ard.2007.087288","volume":"68","author":"MJ Harrison","year":"2009","unstructured":"Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL, et al. British Society for Rheumatology Biologics Register Control Centre Consortium. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2009;68:209\u201315.","journal-title":"Ann Rheum Dis"},{"key":"296_CR24","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1159\/000235582","volume":"219","author":"A Esmailzadeh","year":"2009","unstructured":"Esmailzadeh A, Yousefi P, Farhi D, Bachmeyer C, Cosnes J, Berenbaum F, et al. Predictive factors of eczema-like eruptions among patients without cutaneous psoriasis receiving infliximab: a cohort study of 92 patients. Dermatology. 2009;219:263\u20137.","journal-title":"Dermatology"},{"key":"296_CR25","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1002\/acr.22096","volume":"65","author":"MV Hern\u00e1ndez","year":"2013","unstructured":"Hern\u00e1ndez MV, Sanmart\u00ed R, Ca\u00f1ete JD, Descalzo MA, Alsina M, Carmona L, et al. Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases. Arthritis Care Res. 2013;65:2024\u201331.","journal-title":"Arthritis Care Res."},{"key":"296_CR26","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.cgh.2010.07.022","volume":"8","author":"JF Rahier","year":"2010","unstructured":"Rahier JF, Buche S, Peyrin-Biroulet L, Bouhnik Y, Duclos B, Louis E, et al. Groupe d\u2019\u00e9tude th\u00e9rapeutique des affections inflammatoires du tube digestif [GETAID]. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol. 2010;8:1048\u201355.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"296_CR27","doi-asserted-by":"publisher","unstructured":"Trattner H, Bl\u00fcml S, Steiner I, Plut U, Radakovic S, Tanew A. Quality of life and comorbidities in palmoplantar pustulosis: a cross sectional study on 102 patients. J Eur Acad Dermatol Venereol. Epub 2 Mar 2017. doi:10.1111\/jdv.14187.","DOI":"10.1111\/jdv.14187"},{"key":"296_CR28","first-page":"B4179","volume":"57","author":"A Faurschou","year":"2010","unstructured":"Faurschou A. Role of tumor necrosis factor-\u03b1 in the regulation of keratinocyte cell cycle and DNA repair after ultraviolet-B radiation. Dan Med Bull. 2010;57:B4179.","journal-title":"Dan Med Bull"},{"key":"296_CR29","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/bjd.12779","volume":"170","author":"B Nardone","year":"2014","unstructured":"Nardone B, Hammel JA, Raisch DW, Weaver LL, Schneider D, West DP. Melanoma associated with tumour necrosis factor-\u03b1 inhibitors: a Research on Adverse Drug events And Reports [RADAR] project. Br J Dermatol. 2014;170:1170\u20132.","journal-title":"Br J Dermatol"},{"key":"296_CR30","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1136\/annrheumdis-2016-209285","volume":"76","author":"LK Mercer","year":"2017","unstructured":"Mercer LK, Askling J, Raaschou P, Dixon WG, Dreyer L, Hetland ML, et al. Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. Ann Rheum Dis. 2017;76:386\u201391.","journal-title":"Ann Rheum Dis"},{"key":"296_CR31","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1097\/MIB.0b013e3182802c07","volume":"19","author":"J Torres","year":"2013","unstructured":"Torres J, Buche S, Delaporte E, Colombel JF. Skin side effects of inflammatory bowel disease therapy. Inflamm Bowel Dis. 2013;19:1086\u201398.","journal-title":"Inflamm Bowel Dis"},{"key":"296_CR32","doi-asserted-by":"crossref","first-page":"267","DOI":"10.15403\/jgld.2014.1121.233.mrmk","volume":"23","author":"MR McKenna","year":"2014","unstructured":"McKenna MR, Stobaugh DJ, Deepak P. Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-\u03b1 inhibitor monotherapy and in combination with thiopurines: analysis of the Food and Drug Administration Adverse Event Reporting System. J Gastrointestin Liver Dis. 2014;23:267\u201371.","journal-title":"J Gastrointestin Liver Dis."},{"key":"296_CR33","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1111\/jdv.12675","volume":"29","author":"PP van L\u00fcmig","year":"2015","unstructured":"van L\u00fcmig PP, Menting SP, van den Reek JM, Spuls PI, van Riel PL, van de Kerkhof PC, et al. An increased risk of non-melanoma skin cancer during TNF-inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease-related factors. J Eur Acad Dermatol Venereol. 2015;29:752\u201360.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5 Suppl","key":"296_CR34","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1016\/j.jaad.2006.12.024","volume":"56","author":"GJ Fulchiero Jr","year":"2007","unstructured":"Fulchiero GJ Jr, Salvaggio H, Drabick JJ, Staveley-O\u2019Carroll K, Billingsley EM, Marks JG, et al. Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies. J Am Acad Dermatol. 2007;56(5 Suppl):S65\u20137.","journal-title":"J Am Acad Dermatol"},{"key":"296_CR35","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.jaad.2014.03.005","volume":"70","author":"M Tauber","year":"2014","unstructured":"Tauber M, Buche S, Reygagne P, Berthelot JM, Aubin F, Ghislain PD, et al. Alopecia areata occurring during anti-TNF therapy: a national multicenter prospective study. J Am Acad Dermatol. 2014;70:1146\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"296_CR36","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1159\/000342503","volume":"225","author":"F Osorio","year":"2012","unstructured":"Osorio F, Magro F, Lisboa C, Lopes S, Macedo G, Bettencourt H, et al. Anti-TNF-alpha induced psoriasiform eruptions with severe scalp involvement and alopecia: report of five cases and review of the literature. Dermatology. 2012;225:163\u20137.","journal-title":"Dermatology"},{"key":"296_CR37","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jaad.2008.10.060","volume":"61","author":"AE Moustou","year":"2009","unstructured":"Moustou AE, Matekovits A, Dessinioti C, Antoniou C, Sfikakis PP, Stratigos AJ. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. J Am Acad Dermatol. 2009;61:486\u2013504.","journal-title":"J Am Acad Dermatol"},{"key":"296_CR38","first-page":"769","volume":"7","author":"G Mocci","year":"2013","unstructured":"Mocci G, Marzo M, Papa A, Armuzzi A, Guidi L. Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease J Crohns Colitis. 2013;7:769\u201379.","journal-title":"Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease J Crohns Colitis."},{"key":"296_CR39","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1084\/jem.20112258","volume":"209","author":"CW Franzke","year":"2012","unstructured":"Franzke CW, Cobzaru C, Triantafyllopoulou A, L\u00f6ffek S, Horiuchi K, Threadgill DW, et al. Epidermal ADAM17 maintains the skin barrier by regulating EGFR ligand-dependent terminal keratinocyte differentiation. J Exp Med. 2012;209:1105\u201319.","journal-title":"J Exp Med"},{"key":"296_CR40","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.det.2016.07.006","volume":"35","author":"T Takahashi","year":"2017","unstructured":"Takahashi T, Gallo RL. The critical and multifunctional roles of antimicrobial peptides in dermatology. Dermatol Clin. 2017;35:39\u201350.","journal-title":"Dermatol Clin"},{"key":"296_CR41","first-page":"223","volume":"143","author":"GC de Gannes","year":"2007","unstructured":"de Gannes GC, Ghoreishi M, Pope J, Russell A, Bell D, Adams S, et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol. 2007;143:223\u201331.","journal-title":"Arch Dermatol"},{"key":"296_CR42","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1111\/j.1365-2133.2009.09329.x","volume":"161","author":"J Seneschal","year":"2009","unstructured":"Seneschal J, Milpied B, Vergier B, Lepreux S, Schaeverbeke T, Ta\u00efeb A. Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments. Br J Dermatol. 2009;161:1081\u20138.","journal-title":"Br J Dermatol"},{"key":"296_CR43","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/j.1468-3083.2012.04582.x","volume":"27","author":"M Afshar","year":"2013","unstructured":"Afshar M, Martinez AD, Gallo RL, Hata TR. Induction and exacerbation of psoriasis with Interferon-alpha therapy for hepatitis C: a review and analysis of 36 cases. J Eur Acad Dermatol Venereol. 2013;27:771\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"296_CR44","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/1523-1747.ep12289702","volume":"108","author":"JM Carroll","year":"1997","unstructured":"Carroll JM, Crompton T, Seery JP, Watt FM. Transgenic mice expressing IFN-gamma in the epidermis have eczema, hair hypopigmentation, and hair loss. J Invest Dermatol. 1997;108:412\u201322.","journal-title":"J Invest Dermatol."},{"key":"296_CR45","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nm1162","volume":"11","author":"S Sano","year":"2005","unstructured":"Sano S, Chan KS, Carbajal S, Clifford J, Peavey M, Kiguchi K, et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med. 2005;11:43\u20139.","journal-title":"Nat Med"},{"key":"296_CR46","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/1346-8138.12367","volume":"41","author":"A Ueyama","year":"2014","unstructured":"Ueyama A, Yamamoto M, Tsujii K, Furue Y, Imura C, Shichijo M, et al. Mechanism of pathogenesis of imiquimod-induced skin inflammation in the mouse: a role for interferon-alpha in dendritic cell activation by imiquimod. J Dermatol. 2014;41:135\u201343.","journal-title":"J Dermatol"},{"key":"296_CR47","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1136\/ard.2010.137422","volume":"70","author":"D Salmon-Ceron","year":"2011","unstructured":"Salmon-Ceron D, Tubach F, Lortholary O, Chosidow O, Bretagne S, Nicolas N, et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis. 2011;70:616\u201323.","journal-title":"Ann Rheum Dis"},{"key":"296_CR48","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","volume":"10","author":"M Harbord","year":"2016","unstructured":"Harbord M, Annese V, Vavricka SR, Allez M, Barreiro-de Acosta M, Boberg KM, et al. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016;10:239\u201354.","journal-title":"J Crohns Colitis."},{"key":"296_CR49","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1684\/ejd.2013.2221","volume":"23","author":"M Tauber","year":"2013","unstructured":"Tauber M, Beneton N, Reygagne P, Bachelez H, Viguier M. Alopecia areata developing during ustekinumab therapy: report of two cases. Eur J Dermatol. 2013;23:912\u20133.","journal-title":"Eur J Dermatol."},{"key":"296_CR50","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jaci.2015.11.001","volume":"137","author":"E Guttman-Yassky","year":"2016","unstructured":"Guttman-Yassky E, Ungar B, Noda S, Suprun M, Shroff A, Dutt R, et al. Extensive alopecia areata is reversed by IL-12\/IL-23p40 cytokine antagonism. J Allergy ClinImmunol. 2016;137:301\u20134.","journal-title":"J Allergy ClinImmunol."},{"key":"296_CR51","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/j.dld.2016.08.122","volume":"48","author":"PA Pijls","year":"2016","unstructured":"Pijls PA, Gilissen LP. Vedolizumab is an effective alternative in inflammatory bowel disease patients with anti-TNF-alpha therapy-induced dermatological side effects. Dig Liver Dis. 2016;48:1391\u20133.","journal-title":"Dig Liver Dis."},{"key":"296_CR52","doi-asserted-by":"publisher","first-page":"236","DOI":"10.14309\/crj.2015.70","volume":"9","author":"A Hirsch","year":"2015","unstructured":"Hirsch A, Colman RJ, Lang GD, Rubin DT. Successful treatment of ulcerative colitis with vedolizumab in a patient with an infliximab-associated psoriasiform rash. ACG Case Rep J. 2015;9:236\u20138.","journal-title":"ACG Case Rep J."},{"key":"296_CR53","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.cgh.2016.06.025","volume":"15","author":"L Peyrin-Biroulet","year":"2017","unstructured":"Peyrin-Biroulet L, Van Assche G, G\u00f3mez-Ulloa D, Garc\u00eda-\u00c1lvarez L, Lara N, Black CM, et al. Systematic review of tumor necrosis factor antagonists in extraintestinal manifestations in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2017;15:25\u201336.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"296_CR54","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3109\/08916934.2013.873414","volume":"47","author":"AV Marzano","year":"2014","unstructured":"Marzano AV, Borghi A, Meroni PL, Crosti C, Cugno M. Immune-mediated inflammatory reactions and tumors as skin side effects of inflammatory bowel disease therapy. Autoimmunity. 2014;47:146\u201353.","journal-title":"Autoimmunity."},{"key":"296_CR55","doi-asserted-by":"publisher","first-page":"e1818","DOI":"10.1097\/MD.0000000000001818","volume":"94","author":"AV Marzano","year":"2015","unstructured":"Marzano AV, Tavecchio S, Berti E, Gelmetti C, Cugno M. Paradoxical autoinflammatory skin reaction to tumor necrosis factor alpha blockers manifesting as amicrobial pustulosis of the folds in patients with inflammatory bowel diseases. Medicine [Baltimore]. 2015;94:e1818.","journal-title":"Medicine [Baltimore]."},{"key":"296_CR56","doi-asserted-by":"publisher","first-page":"e2301","DOI":"10.1097\/MD.0000000000002301","volume":"94","author":"AV Marzano","year":"2015","unstructured":"Marzano AV, Tavecchio S, Berti E, Gelmetti C, Cugno M. Cytokine and chemokine profile in amicrobial pustulosis of the folds: evidence for autoinflammation. Medicine [Baltimore]. 2015;94:e2301.","journal-title":"Medicine [Baltimore]."},{"key":"296_CR57","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/ard.2005.037424","volume":"65","author":"S Kary","year":"2006","unstructured":"Kary S, Worm M, Audring H, Huscher D, Renelt M, S\u00f6rensen H, et al. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists. Ann Rheum Dis. 2006;65:405\u20137.","journal-title":"Ann Rheum Dis"},{"key":"296_CR58","doi-asserted-by":"publisher","unstructured":"Darrigade AS, Milpied B, Truchetet ME, Schaeverbeke T, Laharie D, Zerbib F, et al. Pattern and severity of psoriasiform eruptions in patients with inflammatory bowel diseases, arthritis or skin inflammatory disorders treated with TNF alpha inhibitors. Acta Derm Venereol. Epub 20 Feb 2017. doi:10.2340\/00015555-2636.","DOI":"10.2340\/00015555-2636"},{"key":"296_CR59","doi-asserted-by":"publisher","unstructured":"Dequidt L, Cogrel O, Guillet S, Milpied B, Darrigade AS, Beylot-Barry M, et al. Paradoxical psoriasiform reactions to anti-TNF\u03b1 drugs in hidradenitis suppurativa. Br J Dermatol. Epub 26 Apr 2017. doi:10.1111\/bjd.15616.","DOI":"10.1111\/bjd.15616"},{"key":"296_CR60","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1097\/MIB.0000000000000198","volume":"20","author":"M Friedrich","year":"2014","unstructured":"Friedrich M, Tillack C, Wollenberg A, Schauber J, Brand S. IL-36\u03b3 sustains a proinflammatory self-amplifying loop with IL-17C in anti-TNF-induced psoriasiform skin lesions of patients with Crohn\u2019s disease. Inflamm Bowel Dis. 2014;20:1891\u2013901.","journal-title":"Inflamm Bowel Dis"},{"key":"296_CR61","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1080\/1744666X.2016.1221762","volume":"12","author":"CC Zouboulis","year":"2016","unstructured":"Zouboulis CC. Adalimumab for the treatment of hidradenitis suppurativa\/acne inversa. Expert Rev Clin Immunol. 2016;12:1015\u201326.","journal-title":"Expert Rev Clin Immunol."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-017-0296-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-017-0296-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-017-0296-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T09:51:39Z","timestamp":1659088299000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-017-0296-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,8]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["296"],"URL":"https:\/\/doi.org\/10.1007\/s40257-017-0296-7","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,8]]},"assertion":[{"value":"8 June 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was received for the preparation of this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Siegfried Segaert and Caroline Hermans have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}